Prophylactic thyroidectomy in multiple endocrine neoplasia type 2

References

• Mulligan LM, Kwok JB, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature363(6428), 458–460 (1993).
   PubMed Web of Science ®Google Scholar
• Donis-Keller H, Dou S, Chi D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet.2(7), 851–856 (1993).
   PubMed Web of Science ®Google Scholar
• Raue F, Frank-Raue K, Grauer A. Multiple endocrine neoplasia type 2. Clinical features and screening. Endocrinol. Metab. Clin. North Am.23(1), 137–156 (1994).
   PubMedGoogle Scholar
• Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2. Fam. Cancer9(3), 449–457 (2010).
   PubMed Web of Science ®Google Scholar
• Farndon JR, Leight GS, Dilley WG et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br. J. Surg.73(4), 278–281 (1986).
   PubMed Web of Science ®Google Scholar
• Elisei R, Romei C, Cosci B et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J. Clin. Endocrinol. Metab.92(12), 4725–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Lips CJ, Landsvater RM, Hoppener JW et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N. Engl. J. Med.331(13), 828–835 (1994).
   PubMed Web of Science ®Google Scholar
• Frank-Raue K, Buhr H, Dralle H et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur. J. Endocrinol.155(2), 229–236 (2006).
   PubMedGoogle Scholar
• Machens A, Niccoli-Sire P, Hoegel J et al. Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J. Med.349(16), 1517–1525 (2003).
   PubMed Web of Science ®Google Scholar
• Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N. Engl. J. Med.353(11), 1105–1113 (2005).
   PubMedGoogle Scholar
• Mathew CG, Smith BA, Thorpe K et al. Deletion of genes on chromosome 1 in endocrine neoplasia. Nature328(6130), 524–526 (1987).
   PubMed Web of Science ®Google Scholar
• Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. Mol. Cell. Endocrinol.322(1–2), 2–7 (2010).
   PubMed Web of Science ®Google Scholar
• Kloos RT, Eng C, Evans DB et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid19(6), 565–612 (2009).
   PubMed Web of Science ®Google Scholar
• Frank-Raue K, Rondot S, Schulze E, Raue F. Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin. Lab.53(5–6), 273–282 (2007).
   Google Scholar
• Romei C, Mariotti S, Fugazzola L et al. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur. J. Endocrinol.163(2), 301–308 (2010).
   Google Scholar
• LiVolsi VA. C cell hyperplasia/neoplasia. J. Clin. Endocrinol. Metab.82(1), 39–41 (1997).
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Shapiro SE, Perrier ND et al.RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid15(6), 531–544 (2005).
   PubMed Web of Science ®Google Scholar
• Yip L, Cote GJ, Shapiro SE et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch. Surg.138(4), 409–416 (2003).
   PubMedGoogle Scholar
• Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab.86(12), 5658–5671 (2001).
   PubMed Web of Science ®Google Scholar
• Frank-Raue K, Machens A, Scheuba C, Niederle B, Dralle H, Raue F. Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Clin. Endocrinol. (Oxf.)69(2), 259–263 (2008).
   Google Scholar
• Niccoli-Sire P, Murat A, Rohmer V et al. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. J. Clin. Endocrinol. Metab.86(8), 3746–3753 (2001).
   Google Scholar
• Zenaty D, Aigrain Y, Peuchmaur M et al. Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B. Eur. J. Endocrinol.160(5), 807–813 (2009).
   Google Scholar
• Frohnauer MK, Decker RA. Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery128(6), 1052–1058 (2000).
   Google Scholar
• Feldman GL, Edmonds MW, Ainsworth PJ et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG–>ATG) mutation. Surgery128(1), 93–98 (2000).
   PubMedGoogle Scholar
• Musholt TJ, Hanack J, Brehm C, von Wasielewski R, Musholt PB. Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display. World J. Surg.29(4), 472–482 (2005).
   Google Scholar
• Cohen R, Campos JM, Salaun C et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d’Etudes des Tumeurs a Calcitonine (GETC). J. Clin. Endocrinol. Metab.85(2), 919–922 (2000).
   PubMed Web of Science ®Google Scholar
• Sakorafas GH, Friess H, Peros G. The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy. Endocr. Relat. Cancer15(4), 871–884 (2008).
   Google Scholar
• Schreinemakers JM, Vriens MR, Valk GD et al. Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study. World J. Surg.34(4), 852–860 (2010).
   Google Scholar
• Machens A, Lorenz K, Dralle H. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann. Surg.250(2), 305–310 (2009).
   Google Scholar
• Heizmann O, Haecker FM, Zumsteg U, Muller B, Oberholzer M, Oertli D. Presymptomatic thyroidectomy in multiple endocrine neoplasia 2a. Eur. J. Surg. Oncol.32(1), 98–102 (2006).
   Google Scholar
• Niccoli-Sire P, Murat A, Baudin E et al. Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC). Eur. J. Endocrinol.141(5), 468–474 (1999).
   Google Scholar
• Gimm O, Ukkat J, Niederle BE et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J. Surg.28(12), 1312–1316 (2004).
   Google Scholar
• Dralle H, Gimm O, Simon D et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J. Surg.22(7), 744–751 (1998).
   PubMedGoogle Scholar
• Colombo-Benkmann M, Raff J, Raue F, Klar E, Herfarth C. [Effect of primary surgical therapy on the course of C-cell carcinoma of the thyroid gland]. Langenbecks Arch. Chir. Suppl. Kongressbd115, 1041–1043 (1998).
   Google Scholar
• Laure Giraudet A, Al Ghulzan A, Auperin A et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur. J. Endocrinol.158(2), 239–246 (2008).
   PubMedGoogle Scholar
• Ball DW. Medullary thyroid cancer: monitoring and therapy. Endocrinol. Metab. Clin. North Am.36(3), 823–837 viii (2007).
   Google Scholar
• Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J. Clin. Endocrinol. Metab.94(5), 1493–1499 (2009).
   PubMed Web of Science ®Google Scholar